** FILE ** In this July 23, 2007 file photo, Biogen Idec Inc. principle scientist Darren Baker, right, and scientist John Eldridge work on protein purification at a laboratory at the company’s Cambridge, Mass. headquarters. Biogen Idec Inc. said Tuesday its third-quarter profit rose 73 percent on higher sales of the multiple sclerosis drugs Avonex and Tysabri. (AP Photo/Charles Krupa, file)
